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SUMMARY: 
Haemophilia A is one of the most common of the severe coagulation disorders. There are 
approximately 5,400 people in the UK with haemophilia A. Severe (Classical) haemophilia A occurs 
in 40% of cases. Haemophilia A is managed through FVIII replacement therapy. A major 
complication is the development of FVIII IgG antibodies (inhibitors) to FVIII therapy. 
 
Prior to the development of recombinant technology, all FVIII was derived from human plasma 
fractionation. High purity pdFVIII became the standard treatment of choice for haemophilia A. The 
rFVIII products use mammalian cell expression systems in manufacture, and some but not all of the 
products are stabilised using human albumin. The biological and haemostatic characteristics of rFVIII 
have been found to be comparable to pdFVIII products. It has been suggested, but not established, 
that rFVIII may be responsible for a greater level of inhibitor development. 
 
Following the effect of HIV on the haemophilic population up to the mid-1980s, the potential of new, 
as yet unknown, viruses and other agents being inadvertently transmitted to haemophiliacs through 
FVIII concentrates has been of concern. The known risks associated with the currently produced 
pdVIII concentrates are very small with respect to AIDS and Hepatitis B and C, but these products 
are known to transmit other viruses such as parvovirus and Hepatitis A. The risk of Hepatitis A 
infection is very low. With rFVIII there should be no risk of transmitting known blood borne viruses. 
 
The aggregate financial impact of a switch from pdFVIII to rFVIII, with marginal (extra) cost per 
district (population 500,000) per year is in excess of £250,000. It is not possible to quantify benefits 
in terms of direct income, e.g. cost per QALY or life year saved. Indeed, it is difficult to establish any 
tangible benefit from a product switch. However, Haemophilia Centre Directors believe that rFVIII 
may be better placed to contend ZLWKWKHµQH[W¶RUµXQNQRZQ¶YLUXVDQGVHHLQWKHXVHRIU)9,,,WKH
further reduction of risk of viral infection in what has been a long and troubled history. What may be 
obtained from rFVIII is an intangible benefit to patients and their families surrounding perceived risk. 
 
'(&,6,217KH&RPPLWWHH¶VGHFLVLRQZDVQRWXQDQLPRXVEXWDPDMRULW\VXSSRUWHGWKHYLHZ
that recombinant factor VIII should be used only for newly diagnosed haemophiliac patients 
(that is those who have not previously been exposed to plasma derived factor VIII). Some of the 
Committee, however, felt that recombinant factor VIII should not be used at all. The 
Committee agreed that its decision should be reviewed when the price differential between the 
two products is less. The Committee was not convinced that one product is more likely to 
produce antibodies than the other, and the recommendation was made knowing that there is 
little evidence to suggest that the current pdFVIII is responsible for transmitting infections 
more than the rFVIII product.  
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ABOUT THE TRENT INSTITUTE FOR HEALTH SERVICES RESEARCH 
 The Trent Institute for Health Services Research is a collaborative venture between the 
Universities of Leicester, Nottingham and Sheffield with support from NHS Executive Trent.  
 
The Institute: 
 
x provides advice and support to NHS staff on undertaking Health Services Research 
(HSR); 
  
x provides a consultancy service to NHS bodies on service problems; 
  
x provides training in HSR for career researchers and for health service professionals; 
  
x provides educational support to NHS staff in the application of the results of research; 
  
x disseminates the results of research to influence the provision of health care. 
 
The Directors of the Institute are: Professor R L Akehurst (Sheffield); 
     Professor C E D Chilvers (Nottingham); and  
     Professor M Clarke (Leicester).  
Professor Akehurst currently undertakes the role of Institute Co-ordinator. 
 
A Core Unit, which provides central administrative and co-ordinating services, is located in 
Regent Court within the University of Sheffield in conjunction with the School of Health and 
Related Research (ScHARR). 
FOREWORD 
 
Individuals or small groups in each District Health Authority in Trent have historically 
considered evidence on the likely effectiveness of new procedures or therapies in 
conjunction with their cost, making judgements on whether these should be supported. 
Since all or most Health Authorities face the same issues, there tends to be repetition in 
analysis and this can be wasteful of scarce professional expertise. 
 
There are national attempts to remedy this situation by providing information on the 
effectiveness of interventions and these are welcomed. There remains, however, a 
significant gap between the results of research undertaken and their incorporation into 
contracts.  
 
Following a request from purchasers, a network has been established in the Trent Region to 
allow purchasers to share research knowledge about the effectiveness of acute service 
interventions and to determine collectively their purchasing stance. 
 
ScHARR, which houses the Sheffield Unit of the Trent Institute for Health Services 
Research, facilitates a Working Group on Acute Purchasing. A list of interventions for 
consideration is recommended by the purchasing authorities in Trent and approved by the 
Purchasing Authorities Chief Executives (PACE) and the Trent Development and Evaluation 
Committee (DEC). A project team is assembled to undertake each review. This team is 
typically led by a Public Health consultant, includes leading clinicians in the field and a 
support team from ScHARR which provides help including literature searching, health 
economics and modelling. A seminar is then held on the particular intervention where 
purchasers and provider clinicians consider research evidence and agree provisional 
recommendations on purchasing policy. The guidance emanating from the seminars is 
reflected in this series of Guidance Notes. 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 7KH$XWKRUVZRXOG OLNH WR WKDQN'U*HUUDUG'RODQ +DHPRSKLOLD&HQWUH'LUHFWRU4XHHQ¶V
Medical Centre Nottingham), Bio Products Laboratory (Elstree), Mrs Vicky Vidler (Nurse 
3UDFWLWLRQHU 6KHIILHOG &KLOGUHQ¶V +RVSLWDO 3URIHVVRU )( 3UHVWRQ +DHPRSKLOLD &HQWUH
Director, Royal Hallamshire Hospital, Sheffield), Dr Nick Payne (Acting Director of Public 
Health, Sheffield Health), Miss Natalka Kurlak (ScHARR), The Haemophilia Society, those 
in attendance at the Trent Working Group on Acute Purchasing Seminar held in February 
1997 and other Trent NHS colleagues for their support and helpful comments.   
CONTENTS                 Page 
 
EXECUTIVE SUMMARY           1 
 
1. INTRODUCTION           2 
  1.1 General           2 
  1.2 Haemophilia A: Epidemiology        3 
  1.3 Medical Management of Haemophilia A       4 
  1.4 Factor VIII Products         5 
  1.5 Viral Inactivation / Transmission        7 
 
2. RECOMBINANT FACTOR VIII : SUMMARY OF EVIDENCE OF     9
 EFFECTIVENESS     
  2.1 Treatment Effects: Effectiveness        9 
  2.2 Inhibitor Formation         9 
  2.3 Side Effects        11 
  2.4 Infectivity         12 
  2.5 Immunosuppression       16 
 
3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 17
  3.1 Costs of Providing Recombinant Factor VIII    17 
  3.2 Benefits / Consequences       20 
  3.3 Economic Assessment       21 
 
4. OPTIONS FOR PURCHASERS AND PROVIDERS    24 
  4.1 United Kingdom Haemophilia Centre Directors Organisation:    24
        Recommendations 
  4.2 Support Plasma Derived Factor VIII as the Treatment of Choice 30 
 
5.  DISCUSSION AND CONCLUSION      31 
 
APPENDIX A Cost Analysis of Policy Options (Table 4) Reproduced to    33 
    Show Estimates  excluding VAT.     
 
REFERENCES          34 
LIST OF TABLES AND FIGURES             Page 
 
Table 1 Prevalence of Haemophilia A         4 
 
Table 2 Current Viruses Giving Rise to Particular Concern in the     7 
  Treatment of Haemophilia A 
 
Table 3 Wessex Institute of Public Health: Category Rating System.   22
    
 
Table 4 Expected Resource Consequences (£s) of Funding rFVIII    26 
  (Compared with High Purity pdFVIII) in line with the UKHCDO  
  Priority Order. 
 
Table 5 Patient Characteristics: Expected Level of FVIII Consumption   28 
  per Patient per Year and Estimated Annual Marginal Cost per Patient  
  Associated with a Switch from High Purity pdFVIII to rFVIII. 
 
Table 6 Guidance on Time Effects of UKHCDO Policy Options    29 
 
 
Figure 1 Factor VIII Concentrate, Product Costs used in Cost Analysis  18 
   
Figure 2 Estimated Marginal Cost of a Switch from pdFVIII to rFVIII,  19 
  Based on an Annual Consumption of 1.275 Million iu 
  (Typical Purchaser Community of 500,000 Population). 
 
 
   
 1 
EXECUTIVE SUMMARY 
 
The availability of a recombinant alternative to plasma derived factor VIII (pdFVIII), for the 
management of haemophilia A, has focused attention on the potential costs and 
consequences of the recombinant product. This paper considers the issues associated with 
a switch from pdFVIII to recombinant FVIII (rFVIII). 
 
In assessing the available evidence we find that it is not possible to quantify marginal 
benefits resulting from the use of rFVIII.  Much of the perceived benefit available through the 
use of rFVIII, albeit unquantifiable, surrounds the potential for protection against future, as 
yet unknown, viruses/agents. The haemophilic population has suffered greatly from previous 
blood borne viruses (e.g. HIV) and this adds weight to concerns over future viruses/agents.  
Such issues go beyond the traditional cost and benefit approach of the Trent Working 
Group on Acute Purchasing topics which have focused on health gain. 
 
Given present market prices, supporting the use of rFVIII in the management of haemophilia 
A would involve a substantial increase in funding. It is estimated that a typical purchaser 
district with a population of approximately 500,000 would expect to have 20 cases of severe 
haemophilia A and, switching these patients from high purity pdFVIII to rFVIII, would involve 
a marginal (extra) cost in excess of £250,000 per year per purchaser district. 
 
Recombinant FVIII is a therapeutic product which involves the subjective assessment of 
unknown risk and, as such, it is not possible to be conclusive in terms of policy 
recommendations. Therefore, cost analyses are presented which give an insight into the 
opportunity costs associated with the funding of rFVIII across different patient groups, in 
accordance with guidelines recently published by the UK Haemophilia Centre Directors 
Organisation (UKHCDO). Cost analyses are presented which offer some guidance on the 
time effects, years one to five, of introducing rFVIII across either all haemophilia A patients 
or across the specific patient categories used in the UKHCDO guidelines. 
 
 
 
 
 
 
1. INTRODUCTION 
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1.1 General 
 
Haemophilia A is an X-linked recessive genetic disordera of blood coagulation caused by 
diminished or abnormal production of factor VIII (FVIII), a protein present in plasma. It 
occurs as symptomatic disease in males and can be present in a carrier state in females.b   
Haemophilia A can cause prolonged bleeding, either spontaneously or due to a knock or fall.  
Bleeding is typically internal into joint spaces (haemarthroses) and muscles (muscle 
haematoma) throughout the body. The most common sites of joint and muscle bleeds are 
elbow, knee and ankle. Although the condition can be disabling and life threatening, with 
treatment most haemophiliacs can lead a relatively normal life.   
 
Treatment of haemophilia A has been managed through FVIII replacement therapy with the 
infusion of plasma derived FVIII (pdFVIII). The availability (and increased public awareness) 
of a recombinant alternative to pdFVIII for the management of haemophilia A has focused 
attention on the potential costs and consequences of the recombinant product. 
 
This paper considers the issues associated with any switch from pdFVIII to recombinant 
FVIII (rFVIII). The aim of the investigation is to make those responsible for spending 
decisions concerning the treatment of haemophilia A aware of the cost and benefit 
implications of a switch from plasma derived to recombinant FVIII. 
 
The Guidance Note addresses the issues from the perspective of an NHS purchaser and 
begins with an outline of the epidemiology of haemophilia A (Section 1.2). Section 1.3 
considers the medical management of FVIII treatment in haemophilia A, giving a general 
description of the categories of FVIII product available to manage the condition. Section 2 
offers a summary of the evidence relating to the effectiveness of rFVIII as an alternative to 
pdFVIII and highlights important treatment issues. Section 3 discusses the expected costs 
and expected benefits of rFVIII and an economic assessment of the use of rFVIII as an 
alternative to pdFVIII. Policy options are discussed in Section 3 with further discussion in 
Section 4. 
                                                 
a
 Although a number of cases are caused by spontaneous mutation with no familial link. 
b
 It is theoretically possible for a woman to have haemophilia A, however, it is a very rare occurrence. 
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1.2 Haemophilia A : Epidemiology 
 
Haemophilia A is one of the most common of the severe coagulation disorders. There are 
approximately 5,400 people in the UK with haemophilia A.1  Reported prevalence figures for 
haemophilia A vary between 1-20 per 100,000 of the population,2,3,4,5 with 10 cases per 
100,000 being a widely used prevalence marker. Severe (Classical) haemophilia A occurs in 
40% of cases.4 Table 1 details the expected number of haemophilia A cases, both nationally 
DQGIRUDµW\SLFDO¶GLVWULFWSXUFKDVHUFRPPXQLW\RISRSXODWLRQ7DEOHDOVRLQGLFDWHV
the number of subsequently expected severe cases of haemophilia A in the relevant 
populations. 
 
Severity of the clinical course of the disease depends upon the percentage of plasma factor 
VIII activity present compared with normal levels. 
 
x Severe haemophilia A occurs where there is less than 1% of normal FVIII levels,a  and is 
associated with spontaneous bleeding into joints and muscles.   
x Moderate haemophilia A occurs where FVIII activity is between 1% and 5% of normal 
levels, and is associated with occasional spontaneous bleeding and severe bleeding after 
minor injury.   
x Mild haemophilia A occurs where FVIII is between 5% and 25% of normal FVIII levels, 
and is associated with only severe bleeding after major injury.  
         (Hoyer 1994). 4 
 
Incidence figures for haemophilia A are more difficult to determine. New cases of 
KDHPRSKLOLD$DUHFDWHJRULVHGDV µSUHYLRXVO\XQWUHDWHGSDWLHQWV¶ 383VDQGDUHJHQHUDOO\
children or newly identified haemophiliacs. Incidence can only be calculated from the 
Haemophilia Centre Directors (HCD) Annual Returns, which are not widely available in the 
public domain. On average, it is expected that between 55 and 65 new cases of haemophilia 
A (PUPs) present nationally each year.  
 
 
                                                 
a
  Severe disease is sometimes defined as < 2% of normal coagulation factor activity (Introduction to 
haemophilia, 5th Ed, The Haemophilia Society 1995). 
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Table 1: Prevalence of Haemophilia A 
 
PREVALENCE 
RATE 
PER HEAD OF 
POPULATION 
NUMBER OF 
CASES -  
U.K. 
(POP. 58.7 M) 
NUMBER OF 
CASES -  
DISTRICT 
COMMUNITY a 
(POP. 500,000) 
NUMBER OF 
SEVERE CASES 
- U.K.  
(POP. 58.7 M) 
NUMBER OF 
SEVERE CASES 
-  DISTRICT 
COMMUNITY 
(POP. 500,000) 
 
5 per 100,000   2,935   25 1,174 10 
7 per 100,000   4,109   35 1,644 14 
10  per 100,000   5,870   50 2,348 20 
20  per 100,000 11,740 100 4,696 40 
 
a
  Note: It may be that the distribution of haemophilia A patients across the geographical areas is 
variable due to a tendency for such patients to locate themselves near a specialist haemophilia care 
centre.   
 
1.3 Medical Management of Haemophilia A 
 
1.3.1 Treatment 
 
(i) Treatment Regimen 
Haemophilia A is managed through FVIII replacement therapy.  FVIII concentrate is supplied 
as a freeze dried product and it is reconstituted with a small volume of sterile water before 
intravenous injection. Treatment can be through designated care centres or home therapy.   
 
µ2QGHPDQG¶)9,,,UHSODFHPHQWDWKRPHDWWKHWLPHRIKDHPRUUKDJHLVWKHPRVWFRPPRQ
treatment regimen. FVIII prophylaxis, to prevent bleeding episodes and the long-term 
damage that bleeding episodes can cause, can be undertaken in a number of treatment 
regimens.  Prophylaxis can be short-term to prevent bleeding when a patient is intending to 
participate in an activity which involves some risk e.g. some sports. Alternatively, for patients 
undergoing invasive procedures, prophylaxis involves the correction of FVIII levels prior to 
such procedures. Continual and longer-term prophylactic treatment is mostly administered 
over the period of musculo-skeletal development to prevent muscle and joint damage.  
Prophylaxis has become the standard treatment of choice for children with severe 
haemophilia A. 
(ii) Frequency and Dose 
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)RU µRQGHPDQG¶WKHUDS\SDWLHQWVZLWKVHYHUHKDHPRSKLOLD$ZLOOKDYHEHWZHHQDQG
treatments per year,6 whilst those patients with mild to moderate haemophilia A will have 
one to two treatments per year.7 The level of FVIII used per treatment is based on iu per kg 
(body weight) with treatments generally ranging from 500 to 1000 iu of FVIII.7 One injection 
of FVIII is usually effective in treating minor bleeding episodes, although more severe 
bleeds usually need further treatment.   
 
Longer-term FVIII prophylaxis generally involves FVIII replacement therapy three times per 
week, at a dose of 20-24 iu/kg.8 
 
(iii) Inhibitor Formation 
A major complication in the management of haemophilia A is the development of FVIII IgG 
antibodies (inhibitors) to FVIII therapy. Inhibitor formation can impact upon the degree of 
HIIHFWLYHQHVVHIILFDF\RI)9,,, WUHDWPHQWRU UHQGHU LW LQHIIHFWLYH7KHH[WHQWRI WKH µLQKLELWRU
SUREOHP¶ LVGHSHQGHQWXSRQDQWLERG\WLWUH LHWKHOHYHORIDQWLERG\DFWLYLW\3DWLHQWVZLWKD
low antibody titre can continue to benefit from FVIII therapy but at higher doses. Only those 
patients with a high antibody titre, of 10 BU/ml or more,1,9 are resistant to human FVIII 
concentrates. In such circumstances alternative treatment of bleeding episodes is required. 
The highest risk of inhibitor formation occurs in previously untreated patients with severe 
haemophilia,10 whilst in those with mild and moderate disease the incidence of inhibitor 
formation is much lower. 
 
(iv) Treatment of Cases with Significant Factor VIII Inhibitor Formation 
Treatment of those patients with high inhibitor levels can take different forms. Treatment 
options include: (a) the use of high doses of FVIII to swamp the inhibitors and stop the 
bleed; (b) the use of porcine FVIII; and (c) the use of other coagulation factors e.g. FVIIa. 
The treatment of bleeding episodes in patients with inhibitors is a complex, uncertain and 
costly exercise. 
 
1.4 Factor VIII Products 
 
FVIII is used predominantly for the treatment of haemophilia A, a small amount is used for 
WKHWUHDWPHQWRIYRQ:LOOHEUDQG¶VGLVHDVH)9,,,FDQEHGHULYHGIURPKXPDn plasma through 
fractionation, or can be derived from recombinant gene technology. 
1.4.1 Plasma Derived Factor VIII 
 
 6 
Prior to the development of recombinant technology, all FVIII was derived from human 
plasma fractionation. The plasma fractionation process manufactures FVIII concentrates 
from cryoprecipitate, (prepared from fresh frozen plasma) and is able to produce FVIII 
products differing in purity, dependent upon the production process.  In our discussion of 
FVIII concentrates, the two categories of pdFVIII product of interest are termed 
µLQWHUPHGLDWHSXULW\SURGXFW¶ DQG µKLJKSXULW\SURGXFW¶+LJKSXULW\SG)9,,,KDVEHFRPH WKH
standard treatment of choice for haemophilia A.  Although intermediate purity pdFVIII is still 
used in some cases of haemophilia A, it is most commonly used in the treatment of von 
:LOOHEUDQG¶V'LVHDVH 
 
(a) Intermediate Purity Plasma Derived Factor VIII 
Conventionally prepared material with heat treatment methods of viral inactivation. 
 
(b) High Purity Plasma Derived Factor VIII 
These products are treated with a combination of viral inactivation and purification 
processes i.e. solvent detergent treatments followed by chromatographic 
purification techniques.  The two major chromatographic techniques are 
monoclonal antibody chromatography and ion-exchange (or heparin affinity) 
chromatography. 
 
1.4.2 Recombinant Factor VIII 
 
Developments from the mid-1980s have enabled the production of human plasma proteins 
through recombinant DNA technology. A number of techniques have been developed to 
enable the production of recombinant blood products for medical therapy. The available 
(licensed) recombinant FVIII products use mammalian cell expression systemsa in the 
manufacture of FVIII and the final product is stabilised using human albumin. Currently 
licensed recombinant products undergo chromatographic purification techniques during the 
production process. 
 
 
1.5 Viral Inactivation / Transmission 
 
                                                 
a
 Baxter: Recombinate & Centeon: Bioclate both use Chinese Hamster Ovarian cells, whilst Bayer: Kogenate & 
Centeon: Helixate both use Baby Hamster Kidney cells. 
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Up to the early 1980s concerns regarding viral transmission through the infusion of blood 
products mainly surrounded the transmission of hepatitis. The arrival of HIV in the 1980s 
raised the profile of the issue of viral transmission and its prevention quite dramatically.   
HIV has had a very significant impact on the haemophilic population.11 Processes of viral 
inactivation, introduced since the mid-1980s, have proved successful in reducing the risk of 
viral transmission from lipid-enveloped viruses (e.g. HIV, HBV & HCV).  However, the risk of 
viral transmission through non-lipid-enveloped viruses (e.g. HAV & human parvovirus B19) 
has proved more difficult to manage/reduce. 
 
The potential for viral transmission through the infusion of blood products is a major concern 
with any new product of this nature. The current concerns within the treatment of 
haemophiliacs surround the viruses shown in Table 2. HIV, HBV and HCV are those with 
major known clinical significance. Whilst HAV and human parvovirus B19 prove troublesome 
and raise concerns over future viruses, which may be more damaging, they themselves can 
be managed (in the case of HAV), or generally prove to be of little clinical significance (in 
the case of human parvovirus B19).12,13,14 Although the clinical significance of human 
parvovirus B19 is an arguable point, in most cases it causes only mild illness, see Section 
2.4 for further discussion. 
 
Table 2 : Current Viruses Giving Rise to Particular Concern in the  
  Treatment of Haemophilia A. 
 
TRANSMITTABLE DISEASE 
 
STRUCTURE 
 
Human Immunodeficiency Virus (HIV) 
 
lipid-enveloped virus 
 
Hepatitis B Virus (HBV) 
 
lipid-enveloped virus 
 
Hepatitis C Virus (HCV) 
 
lipid-enveloped virus 
 
Hepatitis A Virus (HAV) 
 
non-lipid enveloped virus 
 
Human Parvovirus (B19) 
 
non-lipid enveloped virus 
 
Unknown virus/agent 
 
virus/agent of unknown make-up 
 
 
 
Following the effect of HIV on the haemophilic population up to the mid-1980s, the potential 
of new, as yet unknown viruses and other transmittable agents, being inadvertently 
transmitted to haemophiliacs through FVIII concentrates has been of increasing concern. 
 8 
Viral inactivation processes are now able to reduce the known risks to low level and these 
are discussed further in Section 2 below. 
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2. RECOMBINANT FACTOR VIII : SUMMARY OF EVIDENCE OF 
 EFFECTIVENESS 
 
2.1 Treatment Effects: Effectiveness  
 
The effectiveness of FVIII products in the treatment of bleeding disorders is associated with 
the biological and haemostatic characteristics of the products in practice.    
 
The biological and haemostatic characteristics of rFVIII have been found to be comparable 
to pdFVIII products.15,16,17,18,19 Bray et al,16 after 33 months of clinical experience, put forward 
evidence to support the hypothesis that rFVIII and pdFVIII are biologically identical. Bray et 
DOUHPDUNWKDWµU)9,,,LVVDIHDQGHIIHFWLYHLQWKHWUHDWPHQWRIKDHPRSKLOLD$UHODWHGEOHHGLQJ¶
(op. cit. p2428). Schwartz et al15 in a study involving a total of 107 subjects, found rFVIII to 
be safe and efficacious for the treatment of haemophilia A, with rFVIII having excellent 
haemostasis qualities and biological activity (half-life) comparable to pdFVIII.  Lusher et al,17 
in a multi-centre trial involving 95 previously untreated patients (treatment period 2.4 months 
to 3.5 years; median of 1.5  years), found all patients responded well with no treatment 
failures.  White et al 19 found pdFVIII and rFVIII to be structurally similar and found rFVIII to 
be an effective therapeutic agent for the treatment of haemophilia A. 
 
Other studies supporting the efficacy and effectiveness of rFVIII are cited within the 
literature, however, in the current debate surrounding the switch from pdFVIII to rFVIII, the 
effectiveness of rFVIII is generally accepted as given. 
 
2.2 Inhibitor Formation  
 
The development of inhibitors to rFVIII compared with pdFVIII is a contentious issue. It has 
been suggested that rFVIII may be responsible for a greater level of inhibitor development 
within haemophilia A patients than would be expected through the use of conventional 
pdFVIII.10 
 
Factors exist which make the comparison of inhibitor formation resulting from rFVIII and 
pdFVIII a complex task. The importance of previously untreated patients within studies, 17,20 
retrospective versus prospective trial designs,1 the differing severity of haemophiliacs 
evaluated, and the concentration of inhibitors (i.e. low or high responders) all impact upon 
the interpretation of studies and the clinical significance of the extent of inhibitor formation. 
 10 
Although the development of inhibitors can prove fatal in cases of high inhibitor 
concentration, it is also the case that inhibitor development in a low concentration can prove 
to be of little significance and in some cases transient. 
 
Comment regarding inhibitor formation within haemophilia A has been clouded through the 
use of studies involving patients with a long record of exposure to various FVIII products.  
The relative risk of inhibitor formation is very strongly related to the length of exposure to 
FVIII replacement therapy.10,20,21 The relative risk of inhibitor formation is about four times 
higher for patients under the age of five years than for older patients.20 It is only through 
studies based on previously untreated patients (calculations based on incidence rather than 
prevalence) that true information on the frequency of inhibitor development within 
haemophilia A can be judged (op. cit. p596). 
 
The risk of inhibitor development in patients treated with intermediate purity pdFVIII and high 
purity pdFVIII products has been shown to be similar.1,20,22 
 
With respect to rFVIII, Lusher et al17 examined inhibitor development in a multi-centre trial 
involving 95 previously untreated children, (2.4 months to 3.5 years; median of 1.5 years).  
Of 81 patients tested for antibodies 16 (14 severe and two moderate haemophilia) were 
shown to have formed antibodies to rFVIII. However, in nine of the 16 patients developing 
antibodies the concentration of antibodies was low (<10 BU), or disappeared with time.   
Bray et al16 considering rFVIII in 71 PUPs (severe haemophilia), found 17 developed 
inhibitors; five with a high concentration (>10 BU), and 12 with low concentrations (10BU). 
Schwartz et al15 conducted a study of rFVIII treatment in 107 haemophiliacs, including 20 
previously untreated patients. Five of the 20 PUPs developed antibodies, with all inhibitor 
concentrations except one being low or declining to a low level.   
 
In considering pdFVIII, Guerois et al9 reported on a study of the French haemophilia A 
population treated with a high purity pdFVIII concentrate, from 1988 to 1993. The study 
involved 56 previously untreated patients with a follow-up duration of 1 to 76 months (mean 
of 29 months). Five of the 56 PUPs developed inhibitors, of which only one was a high 
responder. Addiego et al22 in a study of the treatment of haemophilia A using pdFVIII 
+HPRILO0IRXQGWKDWRQO\WZRRIµSUHYLRXVO\XQWUHDWHGSDWLHQWVZLWK)9,,,OHYHOV ¶
developed inhibitors. These 23 patients had received only monoclonally purified 
solvent/detergent treated FVIII concentrate while on study and on post study surveillance 
(p19). 
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Scharrer and Neutzling 21 conducted a review of 13 published inhibitor studies and following 
WKHLU HYDOXDWLRQ FRQFOXGHG WKDW WKHUH ZDV µQR JUHDWHU ULVN IRU FKLOGUHQ ZLWK VHYHUH
haemophilia A receiving monoclonal or recombinant products in acquiring an inhibitor 
FRPSDUHGZLWKSDWLHQWV UHFHLYLQJFRQYHQWLRQDOSURGXFWV¶ S+RZHYHU WKH\ZHQWRQ WR
VD\ WKDW µ  LW LV OLNHO\ WKDW SXULILFDWLRQ RU YLUXV LQDFWLYDWLRQ PHWKRGV PD\ LQIOXHQFH WKH
DQWLJHQLFLW\RIIDFWRU9,,,FRQFHQWUDWHV¶S:LWKLQWKHUHYLHZXQGHUWDNen, only five of the 
studies related exclusively to PUPs. 
 
Although concerns exist as to the inhibitor forming properties of rFVIII, the current literature 
can offer no conclusive evidence to support the belief that rFVIII is more likely to result in 
the development of inhibitors. de Biasi10 highlights that previous reports of inhibitor 
GHYHORSPHQWPDLQO\EDVHGRQSUHYDOHQFHILJXUHVPD\KDYHXQGHUHVWLPDWHGWKHµWUXH¶ULVN
of complication in patients treated with less pure FVIII concentrates (p544). de Biasi et al 
also placed emphasis on factors other than product type which may affect inhibitor 
development, for example, intensity of treatment, viral inactivation procedures, immunologic 
responses of the patient, and genetic predisposition of the patient. 
 
2.3 Side Effects  
 
Studies to date have shown that rFVIII is well tolerated and not associated with significant 
side effects. Lusher et al 17 reported that in 3,315 infusions administered to 95 patients, 
rFVIII concentrate was well tolerated, with three reports of minor adverse reactions (one 
report of urticaria, flushing, and erythema at the infusion site), p454. Bray et al,16 following 
33 months of clinical experience, reported that rFVIII was well tolerated and not associated 
with significant short-term adverse effects. Fukui et al 18 in a pilot clinical study of rFVIII 
reported no adverse reactions attributable to rFVIII found in 178 infusions. 
 
 
 
 
2.4 Infectivity   
 
2.4.1  µ.QRZQ¶5LVN 
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With respect to the known infection risks, concern with pdFVIII has primarily focused on 
HIV, HCV, HBV, HAV and parvovirus B19.  
 
Since the introduction of viral inactivation processes the risk of transmitting HIV, HCV and 
HBV is very small.13,23 These viruses are lipid-enveloped and are very susceptible to 
treatment by solvent/detergent processes. There have been no cases of HIV transmission 
following treatment with clotting factor concentrate reported since 1986.24 Following the 
introduction of solvent/detergent processes in the UK production of FVIII, there have been 
no reported cases of HIV, HBV or HCV.25 
 
Inactivation methods, both heat treatment and solvent/detergent treatment, have been 
shown to be highly effective against HBV and HCV. Fricke et al12 UHSRUWHGWKDWµWKXVIDUQR
patient has been reported that has contracted hepatitis from use of a product treated in this 
ZD\>LHKHDWWUHDWHGDQGVROYHQWGHWHUJHQWWUHDWHG@¶ 
 
Although the transmission of HBV has essentially been stopped,24 it is also important to note 
that a vaccine is available for the prevention of HBV and all haemophilia A patients should 
be protected in this way. HBV can occur as a precore mutant infection, against which the 
vaccine may not prove to be effective, however, such instances are very rare. 
 
7KH8.+DHPRSKLOLD&HQWUH'LUHFWRUV¶&RPPLWWHHKDVSUHYLRXVO\UHIHUUHGWRWKHVXEVWDQWLDO
safety of pdFVIII products26 FRPPHQWLQJ WKDW SG)9,,, SURGXFWV µKDYH D YHU\ VPDOO RU
negligible risk of transmission of HIV- RU KHSDWLWLV YLUXVHV¶ 3ODLQO\ WKH ULVN RI YLUDO
transmission through FVIII concentrate posed by HIV, HBV and HCV is very small. 
 
With HAV and parvovirus B19, the lack of a lipid envelope in the make-up of the virus 
makes it less susceptible to solvent/detergent methods and heat treatment methods have 
not proven as effective as in the case of lipid enveloped viruses i.e they appear relatively 
heat resistant.  
 
Although some cases of HAV have appeared in haemophilia patients, HAV is only rarely 
transmitted by transfusion.27 There have been no cases of HAV transmission reported 
where UK manufactured products have been used. However, a number of cases have been 
reported, within the last few years, in European countries (Germany, Ireland and Belgium), 
all associated with the use of the same FVIII concentrate (Octa V.I., OctaPharma).24 The 
availability of a HAV vaccine should prevent any occurrence of HAV in treated patients. 
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Although the available HAV vaccine is not licensed for infants under one year of age, it is 
rare for a child to be given FVIII replacement therapy prior to walking age i.e. one to two 
years.a  Furthermore, it is also important to note the risk of HAV infection from routes other 
than FVIII concentrate. HAV has a well documented cycle of infection in the general 
population with around 7,000 cases reported annually; school-aged children and young 
adults are most commonly affected.28 
 
Heat treatment against parvovirus B19 has not been effective in preventing the transmission 
of the virus. Parvovirus B19 appears resistant to all current methods of viral inactivation, 
however, due to its high prevalence in the general population,24,29,30 it is possible that 
haemophiliacs may be exposed to parvovirus regardless of the FVIII product used. 
Parvovirus B19 is spread, other than by blood borne infection, via the respiratory tract;31 
infection is common and occurs world-wide.24 Cohen et al30 found parvovirus B19 to be a 
common infection with around 60% of adult populations having specific IgG antibody. A 
study undertaken in Belgium by Peerlinck et al,29 highlighted the high frequency of 
parvovirus B19 infection in patients with haemophilia and age matched controls. Peerlinck et 
al tested for antiparvovirus B19 IgG antibodies in haemophilia A patients and in controls 
finding overall that 93% of haemophilia patients and 75% of controls tested positive. They 
FRQFOXGHGWKDWµLQIHFWLRQVHHPVDOPRVWHQGHPLFLQRXU>%HOJLXP@SRSXODWLRQ¶S 
 
The clinical significance of human parvovirus B19 is a debated issue. Infection with human 
parvovirus B19 is usually asymptomatic or causes a minor feverish illness.32 However, more 
severe illness can occur i.e. transient aplastic crisis in cases with underlying chronic 
haemolytic anaemia or chronic anaemia in immunocompromised hosts.33 Such cases are 
thought to be rare, although the frequency of cases of severe illness is not reported in the 
present literature. A further concern is the effect of parvovirus B19 infection during 
pregnancy. It has been reported that during pregnancy parvovirus B19 infection may result 
in miscarriage or hydrops fetalis,34 although current evidence is not conclusive. However, 
those carriers of haemophilia who may require treatment with FVIII concentrate during 
pregnancy will generally only receive FVIII concentrate in the period immediately prior to 
birth and in some cases the period immediately after birth. 
 
The known risks associated with the use of pdFVIII concentrates are very small with respect 
to HIV, HBV and HCV.  In terms of HAV the risk of infection is very low and the availability of 
an effective vaccine adds further protection. There is a risk of parvovirus B19 infection within 
                                                 
a
 &OLQLFDORSLQLRQSHUVRQDOFRPPXQLFDWLRQZLWK6KHIILHOG&KLOGUHQ¶V+RVSLWDO 
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the general population as well as through the use of pdFVIII concentrate. Whilst parvovirus 
B19 may in some cases result in significant illness, most cases are clinically insignificant. 
 
In the treatment of patients with rFVIII there should be no risk of transmitting known human 
blood borne viruses.13 Although current products are stabilised in human albumin, this 
product has been shown to be virus safe (i.e. known viruses) through a simple heat 
treatment process.35 Over the past 40 years, not a single case of viral transmission through 
the use of albumin has been reported,35 although vigilance with respect to viral transmission 
has not been to the same degree with albumin as it has been with FVIII products.   
 
Although those treated with FVIII products are protected through donor selection, blood 
donation screening, viral inactivation techniques and immunisation programmes, it is also 
necessary to prevent the spread of viral contamination within the manufacturing plant (both 
pdFVIII and rFVIII) and to avoid the recontamination of any process downstream of a point 
where viral infectivity has been reduced or eliminated i.e. good manufacturing practice 
(GMP).36 Throughout the discussion of FVIII concentrate we have so far assumed that GMP 
prevails.  Human error and the failure of GMP is a known risk factor associated with all FVIII 
production processes.   
 
There have been a number of instances where the withdrawal of a product has been 
necessary for safety reasons. One example of this involves the manufacturer Centeon 
L.L.C. (USA).  Due to failures in GMP Centeon L.L.C. has been subject to strict United 
States Food and Drug Administration (FDA) regulations, whilst appropriate GMP measures 
are introduced, including a restriction of trade and distribution.  In September 1996 Centeon 
L.L.C. recalled one lot of human albumin (Albuminar-25) due to contamination with bacterial 
agents. Following this withdrawal, as a precautionary measure, Centeon withdrew a further 
nine additional lots of albumin and one lot of FVIII concentrate (Monoclate-P). 
It is the case that in some instances product withdrawal has been instigated as part of the 
GMP itself and reflects the care taken in the manufacture and distribution of blood products.   
For example, in August 1996 Bio Products Laboratory (BPL) initiated a precautionary recall 
of product which had not been shown to be defective and which complied with UK and 
European regulatory requirements.  However, as part of the industry driven GMP, BPL 
withdrew one batch of FVIII concentrate (Replenate) and 3 batches of albumin (Zenalb) as a 
purely precautionary measure.  The withdrawal was due to concerns over one of the plasma 
pool start donations (BPL Recall of Product: Incident PR96/240). Although the concerns of 
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BPL were of a nature that manufacturing processes would eliminate, the recall decision was 
made to maintain public confidence in the manufacturing process.   
 
Bordering between the known and unknown virus, there is presently some concern 
surrounding Creutzfeldt-Jakob disease (CJD). CJD is a disease of the central nervous 
system and little is known about the risk it poses in terms of blood borne  transmission of 
disease.  It is thought that the disease is caused by an infectious protein or prion which 
affects the normal plasma membrane protein.24 Research is being undertaken to examine 
the possibility of CJD transmission by blood transfusion and some early research is taking 
place (USA and UK) to further examine the occurrence of CJD in the context of 
haemophilia. 
 
2.4.2  µ8QNQRZQ¶5LVN 
 
Much of the literature focusing on viral transmission refers to risks associated with 
µXQNQRZQ¶RUIXWXUHYLUXVHV7KHLVVXHRIµXQNQRZQULVN¶LVDYHU\VXEMHFWLYHFRQFHSWDQGFDQ
only be assessed based on known risk and experience. In the treatment of haemophilia 
using pdFVIII, the transmission of parvovirus B19 through the use of pdFVIII gives rise to 
FRQFHUQV RYHU WKH SRWHQWLDO IRU D µQHZ¶ YLUXV RI VLPLODU VWUXFWXUH EXW ZLWK JUHDWHU FOLQLFDO
significance.  Should such a situation occur it would have dramatic consequences for the 
haemophilia population, yet, given the prevalence of parvovirus B19, the same situation 
would also prevail within the population at large. In the treatment of haemophilia through the 
use of rFVIII, the unknown risk can firstly be associated with the present albumin content of 
WKLVSURGXFWDQGWKHSRVVLELOLW\RID µIXWXUH¶ DV\HWXQNQRZQKXPDQEORRGERUQHYLUXVQRW
being inactivated through the present viral inactivation process.  Future rFVIII products, not 
involving human albumin, are in development and are expected to be marketed soon after 
the year 2000. Secondly, a further area of unknown risk associated with rFVIII lies in the 
possibility of cross-species infection, due to the use of mammalian cell expression systems 
in the production of rFVIII concentrate. The current literature has no direct data to support 
any concerns of cross-species viral transmission from FVIII or similar products.  Although 
the risk of cross-VSHFLHVLQIHFWLRQSRVHGE\U)9,,,LVYHU\VPDOOLQDGLVFXVVLRQRIµXQNQRZQ¶
viruses it is an area with growing theoretical concern. 
 
2.5 Immunosuppression 
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It has been suggested that the deterioration of the immune system of HIV infected 
haemophiliacs, as represented by CD4 lymphocyte counts, may stabilise or be less rapid in 
patients treated with high purity or recombinant FVIII concentrates.37,38,39 Although there is 
no demonstrated benefit in terms of outcome or survival, the findings may be of interest in 
the medical management of HIV infected haemophiliacs.    
 
 
 17 
3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
3.1 Costs of Providing Recombinant Factor VIII 
 
Within the current literature there is little discussion surrounding the aggregate cost 
consequences associated with a switch from pdFVIII to rFVIII. Outlined below are estimates 
of the expected FVIII expenditure per purchasing district, based on a population of 500,000, 
using a prevalence rate of 1 case per 10,000 population. Estimates are calculated based on 
an average FVIII consumption level per patient per year, reported by Haemophilia Centre 
'LUHFWRUV¶+&'$QQXDO5HWXUQV3UHVHQWO\SG)9,,,LVH[HPSWHGIURP9$7ZKHUHDV
rFVIII is VAT chargeable (at a rate of 17.5%). NHS purchases of rFVIII will be subject to 
VAT charges which are non-reclaimable from HM Customs & Excise (VAT Leaflet 
701/31/92, personal communication from HM Customs & Excise). With this VAT issue in 
mind, cost estimates below are discussed including VAT to give D µW\SLFDO SXUFKDVHU¶
SHUVSHFWLYH (VWLPDWHV H[FOXGLQJ 9$7 ZLOO DOVR EH SUHVHQWHG WR RIIHU D µSXEOLF VHFWRU¶
perspective. 
 
3.1.1 Factor VIII Product Costs 
 
There is a wide range of FVIII products available (see United Kingdom Haemophilia Centre 
Directors Organisation (UKHCDO) 1997 guidelines for detail)23 and, due to the competitive 
nature of the market for FVIII concentrates, list prices do not reflect the prices charged to 
purchasers.  For the purpose of the cost analysis undertaken in this Guidance Note the 
prices shown below (Figure 1) will be used as a reflection of average prices charged per iu 
of FVIII. Prices for UK manufactured pdFVIII have been used (i.e. products manufactured by 
BPL). UK manufactured concentrate (BPL) represents over 50% of the FVIII concentrate 
used nationally (HCD Annual Returns 1994). The prices shown are supported by prices 
quoted in the literature40 and both local clinical opinion and manufacturer opinion. However, 
prices are average prices and they may vary between purchasers. 
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Figure 1: Factor VIII Concentrate, Product Costs used in Cost Analysis 
 
 
 Factor VIII    Average Prices  
 Intermediate purity pdFVIII (BPL; 8Y) £0.186 per iu 
 High Purity pdFVIII (BPL; Replenate) £0.27  per iu 
 Recombinant FVIII (all)   £0.47 per iu incl. VAT  - (£0.40 per iu excl. VAT) 
      
 
 
3.1.2 Estimated Annual Costs - Average Annual Factor VIII Consumption Method 
 
The figure reported in HCD 1994 Annual Returns shows a mean FVIII usage per patient 
treated of 63,766 iua  which would result in an annual FVIII consumption of 1.275 million iu, 
for a typical district population of 500,000, across an expected 20 cases of severe 
haemophilia A (assuming 40% of expected cases to be severe haemophilia). This level of 
FVIII consumption finds support in trial data covering FVIII replacement therapy.15 Schwartz 
et al 15 RQWKHEDVLVRIPRQWKV¶KRPHWUHDWPHQWLQSUHYLRXVO\WUHDWHGSDWLHQWVHVWLPDWH
a mean consumption of FVIII to be 78,234 iu per patient per year (range 500iu to 304,022iu 
per year). 
 
Figure 2 details the estimated annual marginal costs associated with a switch from pdFVIII 
to rFVIII. Given an annual FVIII consumption of 1.275 million iu across severe cases of 
haemophilia, per typical purchaser population of 500,000, the estimated marginal costs 
associated with a switch from high purity pdFVIII to rFVIII are £255,064 per year per district 
including VAT. 
 
 
                                                 
a
 The HCD Annual Returns 1994 detail a total FVIII consumption (haemophilia A) of 151 million iu, a total 
number of treated haemophilia A patients of 2,368 and a mean FVIII consumption level  per patient per annum 
of 63,766iu. (The Oxford Haemophilia Centre & Haemophilia Society). 
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Figure 2: Estimated Marginal Cost of a Switch from pdFVIII to rFVIII, Based 
  on an Annual Consumption of 1.275 Million iu (Typical Purchaser 
  Community of 500,000 Population). 
 
 
 On the basis of an annual FVIII consumption of 1.275 million iu, per district 
 community, (average FVIII per patient per year of 63,766 iu- severe cases only) the 
 following estimates of the marginal costs associated with a switch from high purity 
 pdFVIII to rFVIII would apply: 
         Incl. VAT  Excl. VAT
 Marginal cost of rFVIII over high purity pdFVIII  £255,064 £165,791
  
 
3.1.3 Cost - General 
 
The outline cost analysis above identifies the substantial aggregate financial impact of a 
switch from pdFVIII to rFVIII, with a marginal (extra) cost per district per year in excess of 
£250,000. 
 
A further cost consideration for individual purchasers is the magnitude of the resource 
FRQVHTXHQFHV IRU VR FDOOHG µELJ EOHHG HSLVRGHV¶ LH PDMRU EOHHGLQJ HSLVRGHV UHTXLULQJ
considerable medical attention. These episodes are infrequent and clinical opinion suggests 
that, over a purchasing region covering 5 or 6 health authorities, only one major bleeding 
episode may occur per year. This supposition would be supported by the relatively 
infrequent occurrence of inhibitor compromised patients,1 RIWHQDIDFWRUDVVRFLDWHGZLWKµELJ
EOHHGHSLVRGHV¶7KHTXDQWLW\RIPHGLFDWLRQUHTXLUHGWRWUHDWWKHVHHSLVRGHVLVVXEVWDQWLDO
often running into £100,000 plus. A more expensive product, that is rFVIII, may have a 
significant impact on the cost of these individual cases, with the potential to produce a larger 
GHVWDELOLVLQJ HIIHFW RQ WKH SXUFKDVHU¶V EXGJHW +RZHYHU DV GHWDLOHG LQ 6HFWLRQ 3, 
treatment of inhibitor compromised patients (or big bleed episodes) will usually involve 
treatment with products other than FVIII concentrate. 
 
A further consideration is posed through the NHS Special Health Authority status of BPL 
(the UK plasma fractionation operation - England & Wales) which gives rise to the BPL 
RSHUDWLRQEHLQJµXQGHUZULWWHQ¶E\WKH'HSDUWPHQWRI+HDOWK'R+$VVXFKWKH'R+ZRXOG
be liable for any deficit (increased loss) which may result from a switch from pdFVIII to 
rFVIII.  Should BPL products become more costly to produce as a result of reduced demand 
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for pdFVIII (due to issues of joint production) and should BPL be unable to recoup increased 
costs through product prices, due to the highly price sensitive nature of their products (as 
would be expected) it would fall to the DoH to offset any deficit (increased loss) which may 
occur. This may impact upon the general level of aggregate resource available within the 
DoH budget.  Although it is difficult to establish an accurate assesment of any increased 
burden falling on the DoH, BPL estimate that the potential impact on their annual revenue, 
associated with a complete switch from pdFVIII to rFVIII, would be in the region of £15 
million (total revenue in 1995/96 was £48.6 million), whilst plasma purchases would remain 
unchanged i.e. returns from their manufacturing process would be greatly reduced. This 
estimate assumes that no other market for their pdFVIII product is found. 
 
3.2. Benefits / Consequences 
 
It is not possible to quantify benefits in terms of direct outcomes e.g. cost per QALY, or life 
year saved, for a switch from pdFVIII to rFVIII. There is no literature to inform of any 
outcome benefit from rFVIII. Presently it has only been possible to identify the marginal cost 
FRQVHTXHQFHVRIGLIIHULQJWUHDWPHQWSROLFLHVDQGDOOXGHWRWKHµLQWDQJLEOH¶EHQHILWV 
 
Although the area under consideration is an emotional subject, it is difficult to establish any 
tangible benefit from a product switch. The known risks are very small and the potential for 
viral transmission through pdFVIII of lipid-enveloped viruses may be countered with 
arguments showing little actual benefit. 
 
In the case of HAV, a potential benefit could be expected in the form of a reduced risk of 
HAV transmission, although cases of transmission through FVIII are already very rare.  
However, it is possible to address HAV prevention through the use of a relatively 
inexpensive vaccination (Havrix® and Havrix Junior® SmithKline Beecham) which has a very 
good level of effectiveness.  In the case of parvovirus B19, the clinical significance within 
haemophiliacs is regarded as very small,12,13 and the likelihood of exposure within the 
general population is high29,30 (see Section 2.4.1). 
 
7KH SRWHQWLDO IRU VLJQLILFDQW EHQHILWV OLHV ZLWKLQ SDUWLFXODU YLHZV VXUURXQGLQJ µLQWDQJLEOH
EHQHILWV¶DWWULEXWDEOHWRU)9,,,7KHUHLVDEHOLHIDPRQJ+&'VWKDWU)9,,,KDVDGYDQWDJHVZLWK
respect to viral transmission.  These, in view of the known risk of viral transmission, will in 
the main relate to non-lipid enveloped viruses which, as stated above, do not appear to 
represent benefits in terms of patient outcomes. However, there also seems to be a belief 
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DPRQJ+&'VWKDWU)9,,,PD\EHEHWWHUSODFHGWRFRQWHQGZLWKWKHµQH[W¶RUµXQNQRZQ¶YLUXV
It is not possible to quantify future benefits relating to hypothetical future viruses which may 
affect haemophiliacs. It would seem reasonable to hypothesise about future unknown 
viruses, as history has shown that such challenges may appear. However, the source of 
such future unknown viruses is an arguable point. In both pdFVIII and rFVIII there seem to 
be avenues for discussion with respect to the unknown virus. 
 
What may be obtained from rFVIII is an intangible benefit to patients and their families 
surrounding perceived risk. That is, although the risk of known virus transmission is low, it 
may be perceived to be greater by those exposed and, therefore, a perceived reduction 
through rFVIII may constitute a benefit of rFVIII treatment. On the other hand it could be 
argued that educating the haemophilic population to the extent of known risk may offer a 
similar benefit. 
 
Although it is difficult to identify and quantify any tangible benefits, in terms of patient 
outcomes, it may be that such benefits, in this instance health gain, only constitute part of 
the decision-making process. Other ethical and distributional issues may play a significant 
role.  Further discussion of this point is contained in Section 3.3. 
 
3.3 Economic Assessment    
 
Following the above discussions it may be helpful to place the potential costs and 
consequences of a switch from pdFVIII to rFVIII into a wider context, considering the full 
cost and what this cost buys. 
 
An attempt to put the cost and benefit implications in perspective can be framed around the 
guidelines used by The Wessex Institute of Public Health.41 The Wessex guidelines 
consider the scale of the benefits that a purchaser should expect a new therapy to 
demonstrate before it is considered for inclusion in the purchasing process. Part of their 
category rating system is set out in Table 3. 
 
 
 
Table 3: Wessex Institute of Public Health: Category Rating System 41   
 
CATEGORY STATUS 
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(A) <£3,000 per life year gained or Quality Adjusted Life 
Year Gained 
Strongly Recommended 
(B) £3,000  to £20,000 per life year gained or Quality 
Adjusted Life Year Gained 
Recommended 
(C) > £20,000 per life year gained or Quality Adjusted 
Life Year Gained 
Recommended but High Cost 
 
,WKDVQRWEHHQSRVVLEOHWRSXWU)9,,,LQDµFRVWSHU¶IUDPHZRrk as it is not possible to identify 
benefit in terms of patient outcomes. It is possible to consider a marginal treatment cost per 
patient per year (medication cost only). Based on the average annual FVIII consumption per 
patient of 63,766 iu (HCD Annual Returns 1994) and product prices stated in Figure 1, the 
marginal (extra) cost per patient per yeara associated with rFVIII would be approximately 
£12,753 including VAT, when compared with high purity pdFVIII. Given the guidelines used 
by The Wessex Institute of Public Health, therapies with marginal costs in this range would 
need to offer substantial marginal benefit (i.e. one QALY per year) prior to being considered 
for inclusion in the purchasing process. 
 
$V LQGLFDWHG DERYH LW PD\ EH WKDW IRU FHUWDLQ GHFLVLRQV µKHDOWK JDLQ¶ LV RQO\ RQH RI WKH
arguments within a particular decision. The Wessex Institute Guidelines assume a health 
JDLQPD[LPLVLQJREMHFWLYHWKHHPSKDVLVEHLQJXSRQDµFRVWSHU¶DSSURDFKZKLFKPD\QRW
be applicable to all decisions faced by health care purchasers. 
 
In a budget constrained climate, devotion of resources to interventions or therapies of 
XQSURYHQFOLQLFDOEHQHILWKDYHWKHµRSSRUWXQLW\FRVW¶RIKHDOWKJDLQIRUJRQHLQRWKHUDUHDVRI
health service delivery. In discussions surrounding a switch from pdFVIII to rFVIII it is 
important that this point is explicit and that the questions relating to the opportunity costs of 
devoting resources to rFVIII are addressed. Making resources of the magnitude discussed 
above (approx. £250,000 extra per year) available for other evidence-based options will 
most likely result in a net increase in the health gain of the community. Conversely, reducing 
presently provided services, to the extent of the resources required to purchase rFVIII as a 
replacement therapy for pdFVIII, will most likely result in a net loss in the present health gain 
status of the community.   
 
                                                 
a
 As the FVIII consumption figure is an average, this illustrative example is intended to be seen in the context of 
those patients with severe disease, although the HCD Annual Returns cover an average across all treated 
patients. 
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Having raised the issue of opportunity cost and the potential for numerous arguments to be 
competing within a decision making environment LW PD\ EH WKDW VRFLHW\ LV µSUHSDUHG WR
forego efficient health gains in order to behave fairly¶ HPSKDVLV E\ DXWKRU42 Maynard42 
XVHVWKLVHTXLW\FRQFHSWWRGLVFXVVDQDSSURDFKUHIOHFWLQJWKHLGHDRIDµIDLULQQLQJV¶\HWWKH
treatment of the haemophilic population with rFVIII may be regarded as fair by decision 
makers in such a situation. However, should it be the case that decision makers fund rFVIII 
LQRUGHU WR µEHKDYH IDLUO\¶ LW LV LPSRUWDQW WKDW WKH\DUHHQFRXUDJHG WREHH[SOLFLWDERXW WKH
reasoning behind such a decision. 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
4.1 United Kingdom Haemophilia Centre Directors Organisation:  
 Recommendations 
 
,Q D UHFHQW SXEOLFDWLRQ WKH 8.+&'2 RIIHU µJXLGHOLQHV RQ WKHUDSHXWLF SURGXFWV WR WUHDW
KDHPRSKLOLD DQG RWKHU KHUHGLWDU\ GLVRUGHUV¶23 In their specific recommendations for 
haemophilia A they state rFVIII to be their treatment of choice for all patients. 
 
The UKHCDO guidelines23 DOVR LQGLFDWH WKHLU RUGHU RI SDWLHQW SULRULW\ EDVHG RQ µDELOLW\ WR
EHQHILW¶VKRXOG the introduction of rFVIII not be across all patients. They offer the following 
as an order of priority for the introduction of rFVIII in such a case: 
 
(1) HIV antibody negative patients:  
 (a) previously untreated patients 
 (b) HCV negative patients 
 (c) HCV positive patients 
(2) HIV antibody positive patients  
 
To offer some insight into the cost consequences of the above priority ordering the 
proportion of patients likely to be in the above categories has been estimated.   
 
As discussed in Section 1.2 it is difficult to be precise with respect to the true incidence of 
haemophilia A. In the absence of hard data it is estimated, based on HCD Annual Returns 
and clinical opinion, that on average no more than one new case of haemophilia A  would 
present each year per typical purchaser district (500,000 population). It would seem 
reasonable for such a district to expect one new case of severe haemophilia A, previously 
untreated patient, every one to two years. 
 
With respect to the number of HIV antibody positive haemophilia A patients, there is a 
scarcity of published material to call upon.  A study carried out in 1985 by the UKHCD, 43 
covering information on 2,609 patients from 81 haemophilia centres, reported that (a) of 
those patients with severe haemophilia A nearly 60% were HIV positive; (b) of those with 
moderate disease 23% were HIV positive; and (c) of those with mild disease 9% were HIV 
positive. Overall, 44% of those patients with haemophilia A were found to be HIV positive. 
Taking the data from that study it would be expected that, of the estimated 50 haemophilia A 
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patients within a typical district community, (20 severe cases and 30 moderate/mild cases; 
based on a prevalence of 1:10,000), approximately 22 cases would be expected to be HIV 
positive. Of those cases expected to be HIV positive, a large majority would be linked to 
severe cases of haemophilia i.e. 12 out of 20 cases of severe hamophilia A would be 
expected to be HIV antibody positive based on the study conducted in 1985. 
 
In the above assessment of the number of HIV antibody positive haemophilia A patients, it 
would be reasonable to assume that the numbers of HIV positive haemophilia A patients 
indicated by the 1985 UKHCD study are not as applicable to the late 1990s as they were at 
the time of publication. It is expected that the figure given by the UKHCD43 as an estimate of 
HIV positive haemophilia A sufferers (60% of severe cases and 44% overall), would be 
much lower today.  A lower estimate would apply today due to (a) the fact that there has 
been no new case of HIV in the haemophilic population (as a result of FVIII products) since 
1985, as detailed in Section 2.4.1.; and (b) the expectation that a proportion of HIV positive 
cases present in 1985 will have died, either as a result of the virus or due to other causes.  
The impact of HIV on the haemophilic population to date has been to such an extent that, of 
those suffering from severe haemophilia A, it is now expected that, due to a great number of 
HIV related deaths, only 10% to 20% would be expected to be HIV antibody positive.a   That 
is, of the expected 20 cases of severe haemophilia A in a typical purchaser district (500,000 
population) three of these cases would be expected to be HIV antibody positive. 
 
It has also proved difficult to establish the extent of HCV within the haemophilic population, 
given current sources. When deducting those HIV positive haemophiliacs and PUPs from 
the available haemophilic population within a district  (severe cases only) it would leave a 
potential HCV (HIV negative) population of 16 cases. It would seem reasonable for the 
purposes of this outline analysis to assume that 50% to 60% of these cases are HCV 
positive i.e. nine of the 20 cases of severe haemophilia A would be expected to be HCV 
positive.b  
 
Given the patient category calculations above, the priority ordering of the UKHCDO can be 
µURXJKO\¶ FRVWHG RXW DV VKRZQ LQ 7DEOH  ZKLFK GHWDLOV WKH FRVW FRQVHTXHQFHVEDVHGRQ
earlier analysis of FVIII consumption across all known cases of haemophilia A at 63,766 iu 
per patient per year. 
 
                                                 
a
 3HUVRQDOFRPPXQLFDWLRQZLWK'U*'RODQ+DHPRSKLOLD&HQWUH'LUHFWRU4XHHQ¶V0HGLFDO&HQWUH1RWWLQJKDP 
b
 Although this is an arbitrary assumption,  personal communication with The Haemophilia Society offers some 
rationale/support for the figure. 
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Table 4: Expected Resource Consequences (£s) of Funding rFVIII  
  (Compared with High Purity pdFVIII) in line with the UKHCDO  
  Priority Order.  Estimates are Based on Average FVIII   
  Consumption per Patient per Year (63,766 iu, HCD Annual Returns 
  1994) Across Expected Cases of Severe Haemophilia A in a  
  Typical Purchaser District of 500,000 Population. 
 
UKHCDO 
PRIORITY  
ORDER 
GROUPING 
NUMBER 
OF CASES 
µ6(9(5(¶ 
RESOURCE  
CONSEQUENCES  
(INCL. VAT) 
rFVIII VERSUS:  HIGH PURITY 
pdFVIII  
CUMULATIVE RESOURCE 
CONSEQUENCES 
rFVIII VERSUS:  HIGH PURITY 
pdFVIII 
1 (a) 1   £12,753   £12,753 
1 (b) 7   £89,271 £102,024 
1 (c) 9 £114,777 £216,801 
2 3   £38,259 £255,060 
Total 20   
      Please Note: See Appendix A for analysis excluding VAT. 
 
It is important to note that Table 4 is an example, given current information/assumptions and 
the current starting point perspective, to show one possible scenario. It would be expected 
that, in general, groupings 1(c) and 2 (HCV positive patients and HIV positive patients 
respectively) would decline in proportion to the haemophilic population at large and grouping 
1(a), HIV negative PUPS, would grow each year.   
 
Given the above considerations it is important, from a policy perspective, to recognise the 
future implications with respect to the UKHCDO order of patient priority. In applying the 
UKHCDO order of priority for introduction to rFVIII, the groupings 1(a) and 1(b), HIV 
negative PUPs and HIV/HCV negative patients respectively, would constitute a large 
majority of the future haemophilia A population. 
 
A further important issue when considering Table 4 is that using average consumption per 
year data to calculate the marginal costs per patient, the analysis fails to reflect the relatively 
smaller FVIII consumption level which may actually apply to infants. As the level of FVIII 
consumed per patient relates to body weight, it is the case that young children will require a 
lower level of FVIII concentrate per treatment. On the other hand, using an average per 
patient per year level of FVIII consumption also fails to reflect the relatively higher levels of 
FVIII consumption which relate to prophylaxis in patients over 5 years of age. The cost 
analysis undertaken aims to give a broad district-wide estimate of the extra medication costs 
expected following a switch to rFVIII from pdFVIII. The methodology used is based on 
µDYHUDJH¶FRQVXPSWLRQGDWDZKLFKEHVWVXLWV WKH µDFWXDO¶ FRQVXPSWLRQ ILJXUHVDYDLODEOHYLD
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the HCD Annual Returns.  However, to limit any potential misunderstanding which may arise 
from the approach taken in arriving at cost estimates, Table 5 offers guidance on the 
expected level of FVIII consumption per patient per year across differing patient 
characteristics. 
 
:KHQFRQVLGHULQJWKHµH[SHFWHG¶DQQXDOFRQVXPSWLRQOHYHOVSHUSDWLHQWJLYHQLQ7DEOHLW
LVLPSRUWDQWWRQRWHWKDWWKHµDFWXDO¶)9,,,FRQVXPSWLRQOHYHOSHUGLVWULFWSHU\HDUZLOOLQFOXGH
DQ HOHPHQW RI µXQH[SHFWHG¶ )9,,, FRQVXPSWLRQ ZKLFK LV QRW DFFRXQWHG IRU LQ 7DEOH  )Rr 
example, the extended FVIII doses needed in major bleeding episodes and the 
management of inhibitor compromised patients, neither of which may be taken into 
consideration in the consumption estimates given in Table 5. 
 
A further insight, on the time effects of implementing the UKHCDO recommendations, is 
presented in Table 6.  Table 6 incorporates cost estimates discussed in Section 3.1 with the  
estimates of actual FVIII usage across patient categories, discussed in Section 4.1 above 
(Table 5), and the expected mix of severe haemophilia A patients discussed in Section 4.1.  
Although the material presented in Table 6 rests on a number of assumptions, it is able to 
offer some guidance to purchasers concerning specific patient characteristics and the 
consequences of implementing the UKHCDO recommendations across specific patient 
categories.   
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TABLE 5:  Patient Characteristics: Expected Level of FVIII Consumption per 
  Patient per Year and Estimated Annual Marginal Cost per Patient 
  Associated with a Switch from High Purity pdFVIII to rFVIII. 
 
 
 
PATIENT CHARACTERISTICS 
(SEVERE HAEMOPHILIA A) 
EXPECTED ANNUAL 
FVIII CONSUMPTION 
(approx.) 
ESTIMATED 
ANNUAL MARGINAL 
COST 
(incl. VAT) 
Child - Aged Under 1 Yeara   
Regimen : On Prophylaxis 
39,000 iu £7,800 
Child - Aged Under 1 Yeara   
5HJLPHQµ2Q'HPDQG¶ 
2-3,000 iu £200- £600 
Child - Aged Over 1 Year & Under 5 Years 
Regimen : On Prophylaxis 
39,000 iu £7,800 
Child - Aged Over 1 Year & Under 5 Years 
5HJLPHQµ2Q'HPDQG¶b 
 8,200 iu £1,640 
Child - Aged Over 5 Years & Under 12 Years 
Regimen : On Prophylaxis 
78,000 iu £15,600 
Child - Aged Over 5 Years & Under 12 Years 
5HJLPHQµ2Q'HPDQG¶b 
   9,800 iu £1,960 
Child - Aged Over 12 Years & Under 16 Years 
Regimen : On Prophylaxis 
156,000 iu £31,200 
Child - Aged Over 12 Years & Under 16 Years 
5HJLPHQµ2Q'HPDQG¶b 
51,200 iu £10,240 
Adult - Over 16 Years 
Regimen : On Prophylaxisc 
156,000 iu £31,200 
Adult - Over 16 Years 
5HJLPHQµ2Q'HPDQG¶c 
51,200 iu £10,240 
(Source of consumption data:  clinical data from Sheffield &KLOGUHQ¶V+RVSLWDO 
 
a  Note: It is rare for an infant under the age of one to need FVIII replacement therapy; should they 
need treatment they are only likely to be on a  prophylaxis regimen if they have had a major bleeding 
episode.  
 
b Note: Approx. 85% -  RI LQIDQWV ZLWK VHYHUH KDHPRSKLOLD $ WUHDWHG DW 6KHIILHOG &KLOGUHQ¶V
Hospital are on a prophylactic regimen. 
 
c  Note: In the absence of  clinical data  to support the adult consumption of FVIII concentrate those 
figures available for children aged 12-16 yrs of age have been used. 
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TABLE 6 Guidance on Time Effects of UKHCDO Policy Options 
 
A Predicted Pattern of FVIII Consumption and Cost Over Years 1 to 5, Based on the Expected Cases of Severe 
Haemophilia A and the UKHCDO Patient Priority Order.  Costs are Based on the Marginal (extra) Costs Per 
Patient Per Year (incl. VAT) Associated with the use of Recombinant Factor VIII as Opposed to High Purity 
Plasma Derived Factor VIII. 
 
YEARS 
ONE  
& 
TWO 
FVIII POLICY 
(UKHCDO  
PATIENT 
CATEGORIES)a 
EXPECTED 
PATIENTSb 
CONSUMPTION 
OF FVIII (IU)c 
MARGINAL 
COSTd  
£ 
ACCUM. 
MARGINAL 
COST £ 
 1 (a) 1 PUPe   39,000     7,800     7,800 
 1 (b) 7 Virus Freef 675,200 135,040 142,840 
 1 (c) 9 HCV +iveg 565,600 113,120 248,160 
 2 3 HIV +iveh 153,600   30,720 286,680 
 TOTAL 20 Patients   286,680 
      
YEARS 
THREE 
& 
FOUR 
FVIII POLICY 
(UKHCDO  
PATIENT 
CATEGORIES)a 
EXPECTED 
PATIENTSb 
CONSUMPTION 
OF FVIII (IU)c 
MARGINAL 
COSTd  
£ 
ACCUM. 
MARGINAL 
COST £ 
 1 (a) 2 PUPse   78,000  15,600   15,600 
 1 (b) 7 Virus Freef 675,200 135,040 150,640 
 1 (c) 9 HCV +iveg 565,600 113,120 263,760 
 2 2 HIV +iveh 102,400  20,480 284,240 
 TOTAL 20 Patients   284,240 
      
YEAR 
FIVE 
FVIII POLICY 
(UKHCDO  
PATIENT 
CATEGORIES)a 
EXPECTED 
PATIENTSb 
CONSUMPTION 
OF FVIII (IU)c 
MARGINAL 
COSTd  
£ 
ACCUM. 
MARGINAL 
COST £ 
 1 (a) 3 PUPse 117,000  23,400  23,400 
 1 (b) 7 Virus Freef 675,200 135,040 158,440 
 1 (c) 9 HCV +iveg 565,600 113,120 271,560 
 2 1 HIV +iveh   51,200   10,240   281,800 
 TOTAL 20 Patients   281,800 
 
a
  See discussion of UKHCDO recommendations in section 4.1. 
b
  See discussion of expected patient mix in section 4.1. 
c
  See discussion in section 4.1 concerning expected levels of FVIII  consumption across patient type. 
d 
  See discussion of costs in section 3.1. 
e   Assumes 1 new case (PUP) of severe haemophilia every 2 years, per typical district population of 500,000. 
Assumes PUPs present as children aged 1-2 years who are treated on prophylactic regimen. 
f
 Assumes 4 patients at 5-12 years old on prophylactic regimen, 2 patients at 12-16 years old on prophlylactic 
UHJLPHQDQGDGXOWSDWLHQWRQDQµRQGHPDQGµUHJLPHQ 
g Assumes 1 patient at 12-\HDUVROGRQSURSK\ODFWLFUHJLPHQDQGDGXOWSDWLHQWVRQDQµRQGHPDQG¶UHJLPHQ  
h
 Assumes DOO+,9DQWLERG\SRVLWLYHSDWLHQWVLQFDWHJRU\DUHDGXOWVWUHDWHGµRQGHPDQG¶ 
 
Please note that these consumption and cost estimates are based on clinical estimates of FVIII 
consumption across broad categories of patient and do not include unexpected FVIII consumption, for 
example, that used in cases of inhibitor compromised patients or big bleed episodes. 
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4.2 Support Plasma Derived Factor VIII as the Treatment of Choice 
 
The alternative to those policy options discussed in Section 4.1 would be to support the 
conventional treatment of haemophilia A with pdFVIII products as the treatment of choice. 
This policy option should also entail: 
 
Vigilance with respect to new developments in the research literature concerning the further 
development of rFVIII products. 
 
Assessment and monitoring of the vaccination of haemophiliacs against HAV and HBV. 
 
Addressing the current level of anxiety in the haemophilic population by encouraging a 
programme of patient education to explain the very small known risk of viral transmission 
with pdFVIII products. 
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5. DISCUSSION AND CONCLUSION 
 
The assessment of the available evidence relating to the use of rFVIII, as opposed to 
pdFVIII, in the management of haemophilia A, has shown that direct benefit in terms of 
health gain is unquantifiable. The relative merit proposed through the use of rFVIII, as 
advocated through clinical opinion (UKHCDO), would appear to lie in the belief that rFVIII is 
better placed than pdFVIII to contend with future, as yet unknown, viruses and agents. This 
belief, combined with the fact that the haemophilic population has suffered greatly from 
SUHYLRXV µQHZ¶ YLUXVHV HJ +,9 KDV SURPSWHG WKH 8.+&'2 WR SXW IRUZDUG
recommendations for the use of rFVIII as the treatment of choice for all patients.   
 
Cost estimates have been presented showing the expected marginal (extra) annual costs of 
a switch from high purity pdFVIII to rFVIII to be in excess of £250,000, when prescribed 
across all severe haemophilia A patients in a typical purchaser district.  With respect to the  
partial funding of rFVIII across specific patient groups, in accordance with the priority order 
given by the UKHCDO, estimates have also been presented for purchaser guidance.  Based 
on current information and current market prices for FVIII concentrate, the cost associated 
with the funding of rFVIII would appear to have a significant financial impact on any 
purchaser of health care services. 
 
Discussions between the Trent Working Group on Acute Purchasing and clinicians have 
highlighted that conflicting viewpoints are present within the debate surrounding the use of 
rFVIII.  The viewpoint evident from reported clinical opinion (i.e. UKHCDO), is one which 
places emphasis on protection against the threat from the unknown virus/agent.  Whereas, 
purchasers of health care are faced with the need to  maximise, as far as possible,  the 
purchase of health gain subject to finite resources.  Purchasers have many beneficial 
services competing for limited funds and are charged with making decisions surrounding 
which of these beneficial treatments to fund.  In such circumstances costly new technologies 
need to demonstrate substantial marginal benefit prior to being considered for inclusion in 
the purchasing process. 
 
Those seeking funding for the use of rFVIII, must accept that decision makers are placed in 
an unenviable position whereby they must either (i) decide not to fund the use of rFVIII and 
expose themselves to the consequences of the unquantifiable possibility of future infection 
causing viruses being transmitted through pdFVIII, (assuming rFVIII is better placed to 
contend with the unknown virus/agent); or (ii) decide to fund the use of rFVIII (across all 
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patients or across certain patient categories), thereby foregoing the opportunity of 
maximising the overall purchase of health gain for their population. Given the current 
financial climate, the decision to fund rFVIII would ultimately require the withdrawal of health 
care services currently purchased for other sectors of the community. 
 
It is evident from the factors discussed so far that there are issues surrounding the use of 
rFVIII which go beyond the traditional cost and benefit approach of previous topics 
considered by the Trent Working Group on Acute Purchasing. However, it would seem 
reasonable to assume that, if price were not an issue, rFVIII would be adopted as the 
treatment of choice. Therefore, each purchaser must consider the opportunity costs 
associated with the use of rFVIII, within its own local community.  These opportunity costs 
DSSHDUWREHKLJKEDVHGRQWRGD\¶VLQIRUPDWLRQ7KHDQDO\VLVSUHVHQWHGKHUHRIIHUVVRPH
insight into the complete or partial funding of rFVIII within a typical purchaser community.  
 
In the absence of national guidelines and, in the absence of any additional funding to 
accommodate the currently significant costs associated with a switch from pdFVIII to rFVIII, 
purchasers must consider the purchase of rFVIII in the context of the wider health care 
demands of their respective communities. 
 
Due to the controversy and uncertainty associated with the use of rFVIII, a number of 
Purchasing Groups have been assessing the potential use of rFVIII.44,45,46 The initial findings 
of these Purchasing Groups appear to be in line with the presentation made in this report.  
For example, the assessment made by the Northern and Yorkshire Regional Drug and 
Therapeutics Centre44 concludes that, on current evidence, changing all haemophiliacs to 
recombinant products would be premature, with the use of rFVIII across specific patient 
groups being of arguable value. However, such Purchaser Groups have taken differing 
approaches and in most cases work is still being undertaken to refine their views.  
 
Where purchasers are unable to fund rFVIII it will be necessary to address those issues 
discussed in Section 4.2 of this paper. 
 
As product price plays such a large part in the decision to fund the use of rFVIII, it may be 
appropriate to consider placing pressure on manufacturers, where possible, to reduce prices 
and also on Government Officers to address the anomalies which place VAT on the 
purchase of rFVIII. 
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APPENDIX A COST ANALYSIS OF POLICY OPTIONS (TABLE 4)   
   REPRODUCED TO SHOW ESTIMATES  EXCLUDING VAT. 
 
Table 4 (b): Expected Resource Consequences (£s) of Funding rFVIII  
  (Compared with High Purity pdFVIII) in line with the UKHCDO  
  Priority Order. Estimates Exclude VAT and are Based on Average 
  FVIII Consumption per Patient per Year (63,766 iu, HCD Annual 
  Returns 1994) Across Expected Cases of Severe Haemophilia A in 
  a Typical Purchaser District of 500,000 Population. 
 
UKHCDO 
PRIORITY  
ORDER 
GROUPING 
NUMBER 
OF CASES 
µ6(9(5(¶ 
RESOURCE  
CONSEQUENCES  
(EXCL. VAT) 
rFVIII VERSUS: HIGH PURITY 
pdFVIII 
CUMULATIVE RESOURCE 
CONSEQUENCES 
rFVIII VERSUS: HIGH PURITY 
pdFVIII 
1 (a) 1   £8,290   £8,290 
1 (b) 7 £58,030 £68,320 
1 (c) 9 £74,610 £140,930   
2 3 £24,870 £165,800 
Total 20   
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